NASDAQ:HGSI
$27.01
(2/9 12:36PM)
+4.9%
| Open | $26.12 |
Mkt Cap | $4.3 Billion |
| High | $27.19 |
52Wk High | $32.07 |
| Low | $26.02 |
52Wk Low | $0.45 |
| Volume | 2.0 Million |
Avg Vol 10D | 3.5 Million |
Ockham's Rating/Recommendation Summary
Rating specific information requires Premium Access.
Buy Now
or
Learn More about Ockham's Features and Services.
HGSI Revenue
Cash earnings is the most important factor in our analysis, but it goes without saying that if a company cannot produce sales then there is no ability to generate cash flow. By that logic we look very closely at revenue numbers as our second most important factor in valuing a company's stock. We have established reasonable Price to Sales per share ranges based on historical data of the last 10 years. For, HGSI the high and low end of the Price to Sales per share ratios are 191.35x and 74.15x respectively.
Notice that HGSI's current Price to Sales per share ratio is 18.71x, which is quite a bit below what we consider a normal Price to Sales ratio for this stock. Given normal conditions and a price of $26.75, HGSI is 86% below where we would expect to see it. This will beneficially factor into our final analysis of HGSI as it is not often that this stock sinks to these levels.
HGSI Cash Earnings
Cash (and the ability of a company to generate it) is a pivotal analysis at Ockham Research. With HGSI, we have found that we don't have as many years of positive Cash Earnings as we would like in order to run an analysis. When a company like HGSI has had several years of negative Cash Earnings mixed in with their positive years, it can be difficult to really get a good analysis of their potential. At Ockham, we always advise that Cash is key to any investment, so investors should consider the lack of positive years available as a signal that other types of analysis may need to be more heavily relied upon in HGSI's case.
HGSI Dividends
A positive Ockham rating does not require a company to pay out an inviting dividend or a dividend at all. However, we believe dividends provide a useful measure of a company's inherent expectations. HGSI may pay a dividend at this time; however, there is an insufficient amount of history to incorporate it into our analysis. Therefore, we are not utilizing the dividends or lack thereof in our study. As HGSI more consistent dividend history is made available, we will begin to factor this into the Ockham approach.
Slow Month for News Out of HGSI But Power Lunch Mentions Them
It's been at least a month since we noticed any major news coverage of HGSI, so the story in Power Lunch may get the ball rolling.
As we analyze the results from RazorWire, one thing we do is rank each stock in terms of amount of news coverage. Recently, HGSI has been less covered in the news compared to the rest of our universe of stocks. The crowd at The Motley Fool does not like HGSI and believes that it will Underperform. We consider HGSI as Undervalued at the current price of $28.99. According to our methodology, this stock has appreciation potential based on current fundamentals which only improves if earnings or revenue surprise.
“… HUMAN GENOME SCIENCES may have the first fda approved drug for lupus. Can the star biotech keep on booming? Ceo standing by with answer. > > > …”
News Developing on Countdown to the Closing Bell for HGSI
As always, the latest news on HGSI is available to Ockham clients through RazorWire, and it was mentioned recently on Countdown to the Closing Bell.
Interestingly, overall sentiment looks bearish according to the Motley Fool's CAPS survey, as most of their users see Human Genome Sciences, Inc. underperforming. When taking into account the amount of news coverage each stock normally sees as a percentage of the total, Human Genome Sciences, Inc. has actually sunk a bit in comparison to the others. At present, Ockham has a valuation stance of Undervalued on HGSI, as we could see significant price appreciation based on current fundamentals like cash earnings and revenue.
“… Number five is HUMAN GENOME SCIENCES. It's up and down. Today is up. They are raising the money. Priced offerings at $26. 75. A lot of rumors about a takeover of the company.... …”
Fast Money: What is Happening with Human Genome Sciences, Inc. Now?
Staying informed on the news is invaluable for investors, and RazorWire has captured a recently discussion on HGSI from Fast Money.
The crowd at The Motley Fool does not like HGSI and believes that it will Underperform. When looking at our entire coverage universe and ranking stocks by the attention they receive on RazorWire, it is clear that Human Genome Sciences, Inc. has been talked about more than normal recently. We consider HGSI as Undervalued at the current price of $27.18. According to our methodology, this stock has appreciation potential based on current fundamentals which only improves if earnings or revenue surprise.
“… a drop here for HUMAN GENOME SCIENCES. HGSI was down 3%. > > really it was down on this they're going to sell 12. 5 million shares, putting pressure on the stock. > > …”
Squawk On The Street Has News on HGSI
As always, the latest news on HGSI is available to Ockham clients through RazorWire, and it was mentioned recently on Squawk On The Street.
The crowd at The Motley Fool does not like HGSI and believes that it will Underperform. When looking at our entire coverage universe and ranking stocks by the attention they receive on RazorWire, it is clear that Human Genome Sciences, Inc. has been talked about more than normal recently. We consider HGSI as Undervalued at the current price of $27.97. According to our methodology, this stock has appreciation potential based on current fundamentals which only improves if earnings or revenue surprise.
“… HUMAN GENOME SCIENCES filed for fda approval of a drug for hepatitis c. Farmersmarket. Cnbc. Com. Let's go down to bertha at the nymex > > thank you, mike. …”
Check Out Mad Money's News on HGSI
Go ahead. I didn't mean to interrupt. >> caller: HGSI. Is it still a buy? >> you know what? I think it's another great the stuff they are doing on lupus, I don't know what's going to happen. If it -- if that works out, it's going to be a bigger company than it is. I am staying invested in it. Let's go to robert in florida. >> caller: jim, I want to say
“… an it is. I am staying invested in it. Let's go to robert in florida. >> caller: jim, I want to say …”
Human Genome Sciences, Inc. (HGSI) Discussed on CNBC's Power Lunch
Human Genome Sciences, Inc. is in the news. Find out how this impacts HGSI trading on Ockham Research.
Lot of calls coming in, that can be a little bit of an edge, but overall when you have a lot of calls coming in, there's so many different things happening -- >> you're seeing action in HUMAN GENOME SCIENCES. What we do is we look at $3 billion companies and look at the most calls that have come in over the paths 42 days. We have seen 21 calls were bought -- 21 times calls were bought over puts. Massive calls coming in. So when you see something like that, that tells us there's a
“… and look at the most calls that have come in over the paths 42 days. We have seen 21 calls were bought -- 21 times calls were bought over puts. Massive calls coming in. So when you see something like that, that tells us there's a …”
Human Genome Sciences, Inc. (HGSI) Discussed on Fox Business's Countdown to the Closing Bell
Human Genome Sciences, Inc. is in the news. Find out how this impacts HGSI trading on Ockham Research.
Like us can move promising drugs to patients. >> couldn't agree with you more. >> liz: tom watkins is the ceo of HUMAN GENOME SCIENCES working 12 years on a single drug and they don't have total clarity on the end of takes a long time and risk on behalf of the company. Closing bell in 19 minutes. Cit, big lender to small businesses files for bankruptcy. The s&p losing 2 billion in tarp funds that went in to prop the company up.
“… f the company. Closing bell in 19 minutes. Cit, big lender to small businesses files for bankruptcy. The s&p losing 2 billion in tarp funds that went in to prop the company up. …”
Human Genome Sciences, Inc. (HGSI) Discussed on Fox Business's Countdown to the Closing Bell
Human Genome Sciences, Inc. is in the news. Find out how this impacts HGSI trading on Ockham Research.
Third quarter but the stock is roaring ahead. You're up 700%. For HUMAN GENOME SCIENCES. Do you think you can keep investors happy through the next quarter and maybe 2010? >> the big focus at our company is keep ing keeping patients happy. It looks more real than ever. Let's hope we make progress like with benlysta. Other drugs moving through
“… eal than ever. Let's hope we make progress like with benlysta. Other drugs moving through …”
Human Genome Sciences, Inc. (HGSI) Discussed on Fox Business's Countdown to the Closing Bell
Human Genome Sciences, Inc. is in the news. Find out how this impacts HGSI trading on Ockham Research.
To a year ago, not good for stock. >> intel, I remind you was a $12 stock. They have come fighting back. Shibani? >> I know you're speaking to the HUMAN GENOME SCIENCES ceo but it's not HUMAN GENOME SCIENCES active. You're hot or not in the there are big-time swings in you got to talk about the the company, fda response for its bone drug and obviously the news is not good. >> shibani, thank you for putting spin on that. Lupus sufferers, let's get to this, may have new hope.
“… time swings in you got to talk about the the company, fda response for its bone drug and obviously the news is not good. >> shibani, thank you for putting spin on that. Lupus sufferers, let's get to this, may have new hope. …”
Human Genome Sciences, Inc. (HGSI) Discussed on Fox Business's Countdown to the Closing Bell
Human Genome Sciences, Inc. is in the news. Find out how this impacts HGSI trading on Ockham Research.
Have the guts to swoop in when the stock was cheap. We have stocks to keep an eye on as the trading day wraps up next. One stock that everybody is HUMAN GENOME SCIENCES. Up nearly 30% today on views of a successful lupus drug bringing in the ceo live to ask can what's next? What else is in the pipeline? Bell" continuing in a few moments.
“… sk can what's next? What else is in the pipeline? Bell" continuing in a few moments. …”